Mavoglurant(Mavoglurant) - 药物靶点：mGluR5_在研适应症：物质滥用，戒酒，酒精使用障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

AFQ-056、STP 7、STP7

靶点

mGluR5

作用方式

负变构调节剂

作用机制

mGluR5 负变构调节剂(代谢型谷氨酸受体-5 负变构调节剂)

治疗领域

其他疾病肿瘤神经系统疾病

在研适应症

物质滥用戒酒酒精使用障碍+ [5]

非在研适应症

药物性运动障碍运动失调脆性X综合征+ [6]

原研机构

Novartis Pharma AG

在研机构

Stalicla SA初创企业

National Institute on Drug Abuse

National Institute on Alcohol Abuse & Alcoholism

+ [1]

非在研机构

Novartis Pharmaceuticals Corp.

Novartis Pharmaceuticals Canada, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C19H23NO3

InChIKeyZFPZEYHRWGMJCV-ZHALLVOQSA-N

CAS号543906-09-8

关联

32

项与 Mavoglurant 相关的临床试验

NCT06136195

/ Recruiting临床2期IIT

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

开始日期2024-07-01

申办/合作机构

Yale University

[+1]

NCT06273540

/ Completed临床1期

Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral STP7

This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.
The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).
The secondary objectives are:
* To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine.
* To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day.
* To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).

开始日期2024-04-15

申办/合作机构

Stalicla SA初创企业

[+1]

NCT05203965

/ Recruiting早期临床1期IIT

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

开始日期2022-05-17

申办/合作机构

Yale University

[+1]

100 项与 Mavoglurant 相关的临床结果

登录后查看更多信息

100 项与 Mavoglurant 相关的转化医学

登录后查看更多信息

100 项与 Mavoglurant 相关的专利（医药）

登录后查看更多信息

77

项与 Mavoglurant 相关的文献（医药）

2024-11-01·PSYCHOPHARMACOLOGY

The mGlu5 receptor negative allosteric modulator mavoglurant reduces escalated cocaine self-administration in male and female rats

Article

作者: Vendruscolo, Leandro F ; Acri, Jane B ; Vendruscolo, Janaina C M ; Volkow, Nora D ; Whiting, Kimberly E ; Koob, George F

Abstract:

Rationale:

Cocaine use disorder (CUD) is a brain disorder for which there is no Food and Drug Administration-approved pharmacological treatment. Evidence suggests that glutamate and metabotropic glutamate receptor subtype 5 (mGlu5) play critical roles in synaptic plasticity, neuronal development, and psychiatric disorders.

Objective:

In the present study, we tested the hypothesis that the mGlu5 receptor is functionally involved in intravenous cocaine self-administration and assessed the effects of sex and cocaine exposure history.

Methods:

We used a preclinical model of CUD in rats that were allowed long access (LgA; 6 h/day) or short access (ShA; 1 h/day) to intravenous cocaine (750 µg/kg/infusion [0.1 ml]) self-administration. Rats received acute intraperitoneal or oral administration of the mGlu5 receptor negative allosteric modulator mavoglurant (1, 3, and 10 mg/kg) or vehicle.

Results:

Both intraperitoneal and oral mavoglurant administration dose-dependently reduced intravenous cocaine self-administration in the first hour and in the entire 6 h session in rats in the LgA group, with no effect on locomotion. In the ShA group, mavoglurant decreased locomotion but had no effects on cocaine self-administration. We did not observe significant sex × treatment interactions.

Conclusions:

These findings suggest that the mGlu5 receptor is involved in escalated cocaine self-administration. These findings support the development of clinical trials of mavoglurant to evaluate its potential therapeutic benefits for CUD.

2024-08-27·ZEITSCHRIFT FUR PHYSIKALISCHE CHEMIE-INTERNATIONAL JOURNAL OF RESEARCH IN PHYSICAL CHEMISTRY & CHEMICAL PHYSICS

Homology modeling and molecular docking study of metabotropic glutamate receptor 5 variant F: an attempt to develop drugs for treating CNS diseases

作者: Rashid, Haroon ur ; Ali, Essam A. ; Khan, Khalid ; Umar, Muhammad Naveed ; Ahmad, Nasir ; Ullah, Riaz ; Gulfam, Naila ; Zahoor, Muhammad ; Khan, Sher Wali

Abstract:

G protein-coupled receptors (GPCRs) constitute the largest protein family involved in signal transduction and are the main targets for drug delivery. The metabotropic glutamate receptors (mGluRs) are class C of GPCRs that contribute to the modulation of glutamatergic neurotransmission which regulates vital physiological processes and is recognized as a potential therapeutic target throughout the central nervous system. Intracellular C-terminal domains of mGluR are the main targets for proteins regulating these receptors and are also involved in alternative splicing, regulation by phosphorylation, and modulatory protein-protein interactions. Class C of GPCRs exist as dimers and is mediated by interactions between the venus tryflap domain and the transmembrane domain. The mGluR5 variant F can be regulated by both positive and negative allosteric modulators that can potentiate or inhibit the endogenous ligand and glutamate, respectively. Moreover, mGluR5 is involved in many disorders including fragile X syndrome/autism spectrum disorder, schizophrenia, anxiety, addiction, chronic pain and epilepsy, etc. The main purpose of current computational work is to determine the 3D structures of the target protein and their active sites to design new drug molecules as potential biochemical agents. The 3D model of the mGluR5 variant F was constructed through homology modeling techniques using MOE and I-TESSER programs. RAMPAGE and ERRATE online servers were used for the 3D structure evaluation and validation. Furthermore, the mGluR5 variant F was docked with 20 mavoglurant derivatives that act as antagonists. Mavoglurant derivatives 3, 4, 6, 10, 13, 18, and 19 showed a maximum of four interactions with the mGluR5 variant F, whereas derivatives 7, 8, 9, 11, 12, 15, 16, 17 and 20 showed a maximum of three interactions with the mGluR5 variant F. The remaining four mavoglurant derivatives expressed two interactions each with mGluR5 variant F. The docking score for these derivatives ranged between −15.55 and −08.210 kcal mol−1 suggesting their strong interactions with the mGluR5 variant F. Their 3D structure and docking study provides a potential base for the synthesis of new drug candidates to treat brain disorders.

2024-03-01·The Journal of clinical investigation

Effects of AFQ056 on language learning in fragile X syndrome

Article

作者: Cudkowicz, Merit ; Hagerman, Randi ; Veenstra-VanderWeele, Jeremy ; Harkey, Brittney ; Klingner, Elizabeth ; Berry-Kravis, Elizabeth ; Coffey, Christopher S ; Pearson, Brenda ; Abbeduto, Leonard ; Huff, Trevis ; Tassone, Flora ; Costigan, Michele ; Long, Jeff ; Erickson, Craig A ; Kaufmann, Walter E ; Fedler, Janel ; Staley, Kevin ; Ecklund, Dixie ; Klements, David ; Ethridge, Lauren ; Moshinsky, Michael ; Friedmann, Katherine ; Hoffmann, Anne ; McDuffie, Andrea ; Hessl, David ; Bullard, Lauren

BACKGROUNDFXLEARN, the first-ever large multisite trial of effects of disease-targeted pharmacotherapy on learning, was designed to explore a paradigm for measuring effects of mechanism-targeted treatment in fragile X syndrome (FXS). In FXLEARN, the effects of metabotropic glutamate receptor type 5 (mGluR5) negative allosteric modulator (NAM) AFQ056 on language learning were evaluated in 3- to 6-year-old children with FXS, expected to have more learning plasticity than adults, for whom prior trials of mGluR5 NAMs have failed.METHODSAfter a 4-month single-blind placebo lead-in, participants were randomized 1:1 to AFQ056 or placebo, with 2 months of dose optimization to the maximum tolerated dose, then 6 months of treatment during which a language-learning intervention was implemented for both groups. The primary outcome was a centrally scored videotaped communication measure, the Weighted Communication Scale (WCS). Secondary outcomes were objective performance-based and parent-reported cognitive and language measures.RESULTSFXLEARN enrolled 110 participants, randomized 99, and had 91 who completed the placebo-controlled period. Although both groups made language progress and there were no safety issues, the change in WCS score during the placebo-controlled period was not significantly different between the AFQ056 and placebo-treated groups, nor were there any significant between-group differences in change in any secondary measures.CONCLUSIONDespite the large body of evidence supporting use of mGluR5 NAMs in animal models of FXS, this study suggests that this mechanism of action does not translate into benefit for the human FXS population and that better strategies are needed to determine which mechanisms will translate from preclinical models to humans in genetic neurodevelopmental disorders.TRIAL REGISTRATIONClincalTrials.gov NCT02920892.FUNDING SOURCESNeuroNEXT network NIH grants U01NS096767, U24NS107200, U24NS107209, U01NS077323, U24NS107183, U24NS107168, U24NS107128, U24NS107199, U24NS107198, U24NS107166, U10NS077368, U01NS077366, U24NS107205, U01NS077179, and U01NS077352; NIH grant P50HD103526; and Novartis IIT grant AFQ056X2201T for provision of AFQ056.

12

项与 Mavoglurant 相关的新闻（医药）

2024-09-19

·GlobeNewswire-Health Care

Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor

Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September 19, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental disorders, announced today that Dr. Paulo Fontoura will be joining their drug development team as Chief Scientific and Clinical Development Advisor. Dr. Fontoura will work to support STALICLA’s mission to transform the treatment landscape for neurodevelopmental disorders. Lynn Durham, CEO of STALICLA, said: “We are delighted and humbled to welcome Paulo to the STALICLA team. With his unparalleled insight and unique understanding of CNS drug development and neurodevelopmental disorders, he is strengthening STALICLA’s position as a pioneer in precision neuropsychiatry. Paulo’s expertise will be instrumental in helping us achieve our next milestones, notably our entry into two Phase 2 clinical trials in subgroups of patients with autism spectrum disorder (ASD), each with expected readouts in the coming 24 months.” Dr. Paulo Fontoura is a pioneer in innovative clinical development strategies. During his 16-year tenure at Roche, he served as the Global Head of Neuroscience Clinical Development; he was instrumental in the launch of several groundbreaking medications targeting neurological conditions, including Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and Neuromyelitis Optica Spectrum Disorder (NMOSD), as well as pioneering work on Alzheimer's, Parkinson's, Huntington's disease, and several psychiatric and neurodevelopmental disorders. Specifically, he and his team spearheaded the clinical development of new therapies for Fragile X, Down's and Angelman's syndromes, and the first pharmacological treatment for core symptoms of ASD which reached Phase 3 clinical trials in both adults and children. Additionally, his team co-led the Autism Innovative Medicine Studies (AIMS) including EU-AIMS and AIMS-2-TRIALS public private partnership. Dr. Fontoura has also had an illustrious academic career. He held multiple faculty positions at the New University of Lisbon and Stanford University, where he earned his MD and a PhD in Neuroimmunology and trained as a clinical neurologist. In recognition of his exceptional achievements in the field of neuroscience, he was elected as a Fellow of the American Academy of Neurology in 2022. He currently serves as a visiting professor at the New University of Lisbon and lectures at the European Center of Pharmaceutical Medicine in Basel. Paulo Fontoura MD, PhD, Chief Scientific and Clinical Development Advisor, said: “I am thrilled to join the STALICLA team and help them develop therapies for people with neurodevelopmental disorders. Their approach promises to bring real breakthroughs in this area of great medical need.” About STALICLA: STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental disorders. The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 24 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government. For more information, please visit: www.stalicla.com. Contacts: STALICLA SALynn Durham Founder & Chief Executive Officerlynn.durham@stalicla.com Media & InvestorsChris MaggosCohesion Bureauchris.maggos@cohesionbureau.com+41 79 367 6254 Attachment 20240918 Paulo Fontoura PR_final

临床2期临床3期高管变更

2024-06-28

·GlobeNewswire-Health Care

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms June 27, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The results of the study were published in the peer-reviewed journal Biomedicines, in an article titled “Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD”. Lynn Durham, CEO of STALICLA, highlighted: “This study marks a significant milestone in the advancement of precision medicine for ASD. It is a first-of-its-kind stratification-based approach for clinical development in neurodevelopmental disorders, demonstrating the potential of precision medicine in ASD.” The randomized, double-blind, placebo-controlled phase 1b clinical trial evaluated the safety and tolerability of STP1, a combination of ibudilast and bumetanide, in ASD-Phen1 patients. The clinical trial (registered at clinicaltrials.gov NCT04644003), involved two 14-day treatment phases of ASD-Phen1 patients receiving STP1 or placebo. The results showed that STP1 was well-tolerated with no significant adverse effects reported. Significant and dose-related reductions in gamma power were observed in the whole brains of patients taking STP1, particularly in regions associated with executive function and memory. Additionally, STP1 increased alpha 2 power in frontal and occipital regions, while improving habituation and neural synchronization to auditory chirps. Dr. Craig A. Erickson, Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Medical Center, and the principal investigator of the study, remarked: “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field.” Dr. Laura Pérez-Cano, Head of Discovery at STALICLA and co-author of the study, added: “These findings not only highlight the potential of STP1 as a therapeutic option for ASD-Phen1 patients but also underscore the importance of combining biologically-based patient stratification with quantifiable outcome measures such as EEG that can then be correlated with behavioral measures.” By focusing on a biologically defined subgroup of ASD patients, STALICLA is moving closer to making personalized treatment options a reality for patients with ASD. This approach has the potential to revolutionize the treatment of ASD and other neuropsychiatric conditions. STALICLA is a global, clinical-stage biotechnology company focused on advancing precision medicine for brain disorders. The company has developed a unique neuro precision development platform, DEPI, supported by clinical validation in a first indication: Autism Spectrum Disorder. Its lead neurodevelopmental disorder asset, STP1, is entering Phase 2 trials. Its lead neuropsychiatry asset, STP7 (Mavoglurant), fully funded by the US government, will soon be Phase 3 ready for Cocaine Use Disorder. ‎ The content above comes from the network. if any infringement, please contact us to modify.

临床结果

2024-05-08

·GlobeNewswire-Health Care

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder

May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company's drug-drug interaction (DDI) study of STP7 (Mavoglurant), an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis. The DDI study is the last regulatory requirement in a comprehensive Phase 2 program and completion is expected to trigger initiation of a Phase 3 study in the U.S. in 2025. Lynn Durham, CEO and Founder of STALICLA said, “This DDI study unlocks the opportunity under our Cooperative Research and Development Agreement with the U.S. NIH National Institute of Drug Abuse (NIDA) to begin Phase 3 trials for STP7 in 2025 to address the high unmet medical need of cocaine abuse globally. Results from successfully completed Phase 2 studies for cocaine use disorder (CUD) showed highly convincing and unprecedented efficacy results including increase in abstinence from cocaine use and reduction in co-morbid dependencies such as alcohol abuse with STP7 (Mavoglurant). In addition, STALICLA is investigating alternative therapeutic indications for STP7 (Mavoglurant) to benefit patients with other CNS conditions.” STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). As well as its role in addiction pathophysiology, mGluR5 has been implicated in mood disorders and neurodevelopmental disorders such as Fragile X and autism spectrum disorder. Comprehensive clinical studies by Novartis of STP7 (Mavoglurant) to date have included over 1800 adults for up to 2 years, demonstrating good safety and tolerability and significant reduction in cocaine use and positioning STP7 (Mavoglurant) as a strong candidate therapy for substance use and other CNS disorders. STALICLA SA is a Swiss clinical-stage biopharmaceutical company, pioneering precision treatment in neurodevelopmental and neuropsychiatric disorders. Its AI-driven precision neuro medicine platform has allowed to identify two precision small molecule drug candidates for autism spectrum disorder, STP1 and STP2, both planned to enter Phase 2 trials in 2024. Following the in-licensing of Mavoglurant from Novartis in 2023, STALICLA has also established an advanced mGluR5 NAM platform offering multi-faceted late-stage clinical development opportunities broadening STALICLA’s scope to address wider CNS disease unmet needs. For more information, please visit: www.stalicla.com. The content above comes from the network. if any infringement, please contact us to modify.

临床3期临床结果

100 项与 Mavoglurant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Mavoglurant	-	DB13004

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
物质滥用	临床3期	美国	National Institute on Drug Abuse	2023-03-08
物质滥用	临床3期	美国	Stalicla SA初创企业	2023-03-08
脆性X综合征	临床3期	美国	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	比利时	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	丹麦	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	法国	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	德国	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	以色列	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床3期	意大利	Novartis Pharmaceuticals Corp.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03327792 (CTgov)	临床1期	致幻	34	Mavoglurant (200 mg Mavoglurant)	繭選鑰鹽壓鹽願簾齋製 = 構簾鹽膚繭壓鹽醖獵膚觸簾憲網鹹餘製襯構獵 (鏇鏇鏇製淵簾夢簾獵鹽, 築鹽艱夢構夢繭顧築鹽 ~ 鏇鬱願範壓網淵簾築憲) 更多	-	2024-08-06
				Placebo (Placebo)	繭選鑰鹽壓鹽願簾齋製 = 選鹹憲襯簾糧構齋鹽壓觸簾憲網鹹餘製襯構獵 (鏇鏇鏇製淵簾夢簾獵鹽, 醖願衊廠觸鹽艱襯鹹餘 ~ 蓋網鬱憲糧醖築繭鬱餘) 更多
NCT02920892 (FX-LEARN, CTgov)	临床2期	脆性X综合征	110	placebo+AFQ056 (Placebo Comparator: Double-Blind Placebo With Language Intervention)	觸窪窪獵鹽遞醖遞構艱(襯壓願鬱選積鬱壓蓋糧) = 鹹願淵鏇顧廠築製餘憲觸簾鑰淵衊壓齋壓廠艱 (衊製鑰齋觸淵膚範繭艱, 遞醖糧襯膚夢築襯醖膚 ~ 鹹醖選築膚網餘衊鏇壓) 更多	-	2023-10-10
				AFQ056 (Experimental: Double-Blind AFQ056 With Language Intervention)	觸窪窪獵鹽遞醖遞構艱(襯壓願鬱選積鬱壓蓋糧) = 簾網鹹築艱壓鑰衊糧獵觸簾鑰淵衊壓齋壓廠艱 (衊製鑰齋觸淵膚範繭艱, 襯繭壓廠糧鑰鏇窪憲窪 ~ 憲襯獵壓鹽壓觸築鹹鑰) 更多
NCT03242928 (CTgov)	临床2期	可卡因相关疾病 \| 全身性肉碱缺乏症	68	AFQ056 (AFQ056)	顧鹹選網積醖艱構觸醖(觸簾齋餘遞膚糧艱觸選) = 鏇築壓餘蓋構願衊鹽膚鹹鏇廠築艱壓鹽鏇繭憲 (築積觸顧簾網蓋鹹糧獵, 0.027) 更多	-	2021-02-04
				Placebo (Placebo)	顧鹹選網積醖艱構觸醖(觸簾齋餘遞膚糧艱觸選) = 積蓋鹹窪憲夢觸膚築憲鹹鏇廠築艱壓鹽鏇繭憲 (築積觸顧簾網蓋鹹糧獵, 0.024) 更多
WPC2019	N/A	-	485	Mavoglurant (AFQ056)	淵廠築願網繭鬱壓積鬱(壓網夢範遞餘鬱鬱壓齋) = 蓋願遞遞鑰製構簾願膚築鑰鹽糧餘鏇簾鹹構衊 (積鬱淵鑰網簾窪鹹選醖, -0.65 ~ 0.11) 更多	不佳	2019-06-03
				Placebo	淵廠築願網繭鬱壓積鬱(壓網夢範遞餘鬱鬱壓齋) = 構餘獵餘獵衊鑰襯範蓋築鑰鹽糧餘鏇簾鹹構衊 (積鬱淵鑰網簾窪鹹選醖, -0.09 ~ 0.66) 更多
NCT01348087 (Pubmed \| Sci Rep) 人工标引	临床2期	脆性X综合征	267	mavoglurant	夢衊顧夢糧艱壓鹹選範(積簾築網醖淵網鹹獵願) = 蓋壓壓餘艱醖觸築網顧壓鹽範鑰鏇網襯構淵獵 (襯鬱願蓋製選餘鬱淵鏇 ) 更多	不佳	2018-11-19
NCT01813019 (Pubmed \| Adv Ther) 人工标引	临床2期	强迫症	50	mavoglurant	築觸壓壓範艱網糧製齋(顧齋鬱鬱廠壓襯製繭夢) = 鑰選鏇繭憲膚襯構簾繭網鬱壓網廠簾築襯淵鑰 (鹽膚築鏇壓簾醖鹹顧壓 ) 更多	不佳	2017-02-01
				Placebo	築觸壓壓範艱網糧製齋(顧齋鬱鬱廠壓襯製繭夢) = 築願鑰鹽願夢窪齋淵淵網鬱壓網廠簾築襯淵鑰 (鹽膚築鏇壓簾醖鹹顧壓 ) 更多
NCT01813019 (CTgov)	临床2期	强迫症	50	Placebo (Placebo)	簾艱鹽願獵簾網壓繭繭(壓衊簾憲艱鹹繭憲積醖) = 糧衊壓鹽廠膚餘顧網憲鹽鹽艱網廠齋願範壓鬱 (淵鬱窪鹹鏇襯憲醖壓廠, 1.78) 更多	-	2016-07-21
				AFQ056 (AFQ056)	簾艱鹽願獵簾網壓繭繭(壓衊簾憲艱鹹繭憲積醖) = 夢醖夢廠獵鹹醖艱鬱遞鹽鹽艱網廠齋願範壓鬱 (淵鬱窪鹹鏇襯憲醖壓廠, 1.75) 更多
NCT01385592 (Pubmed) 人工标引	临床2期	药物性运动障碍 \| 帕金森病	-	Mavoglurant	壓獵繭構獵鬱範膚艱願(廠夢願夢製築築鬱蓋膚) = did not reach statistical significance 齋範衊鏇餘獵窪選鑰獵 (糧鑰鏇範廠遞蓋鑰醖繭 )	不佳	2016-07-01
				Placebo
NCT01253629 (Pubmed \| Sci Transl Med) 人工标引	临床2期	脆性X综合征	314	Mavoglurant	蓋鏇齋鏇壓構廠築鹹衊(遞蓋製窪網齋顧醖製鑰) = Neither of the studies achieved 獵廠衊製鑰鹹鬱獵淵鏇 (壓蓋蓋襯膚獵鏇獵餘淵 )	不佳	2016-01-13
				Placebo
NCT01357239 (CTgov)	临床2期	脆性X综合征	139	Placebo	鹹觸範鏇製糧積餘壓範(築窪鏇構窪鑰廠築獵顧) = 願齋醖襯構鹽鏇鏇夢網製壓壓憲遞鏇窪遞積壓 (選夢鬱製艱憲鏇鏇製網, 3.88) 更多	-	2015-05-12